FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk Smoldering Multiple Myeloma By Ogkologos - November 13, 2025 386 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AQUILA study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Finding New Uses for Targeted Therapies for Cancer: Updates from the... November 9, 2023 A tribute to Dame Valerie Beral October 13, 2022 Similar Disease-Free Survival with Extended Intermittent or Continuous Treatment with Letrozole... August 11, 2021 Young Breast Cancer Survivors Without a Germline Pathogenic Variant Have a... April 23, 2024 Load more HOT NEWS When Breast Cancer Patient Comes Into His Shop, Barber Shaves His... FDA Approves Olaparib with Abiraterone and Prednisone (or Prednisolone) for BRCA-mutated... FDA Approves Alpelisib for PIK3CA-Related Overgrowth Spectrum How I Navigated the Challenges of 2 Colorectal Cancer Diagnoses As...
